- The Wall Street Journal•12 hours ago
Bristol-Myers Squibb said its second-quarter revenue rose 17%, again driven by the growth of the pharmaceutical company’s Opdivo cancer immunotherapy and other key drugs.
Bristol-Myers Squibb CompanyNYSE
After hours: 75.150.49 (0.66%) as of 7:57 PM EDT
|Bid||74.75 x 100|
|Ask||75.15 x 300|
|52wk Range||51.82 - 77.12|
|Day's Range||74.50 - 76.48|
|Avg Vol (3m)||5,788,396|
As of 4:02 PM EDT. Market closed.